Verici Dx Achieves Olink Certified Service Provider Status, Expanding Proteomics Capabilities for Transplant Diagnostics
核心洞察
Verici Dx (搜索) has attained Olink (搜索) Certified Service Provider status, enabling Olink-based proteomics assay services from its CAP-certified/CLIA-accredited laboratory.
The certification allows Verici Dx (搜索) to support biomarker discovery, algorithm development, validation, and clinical trial applications for both clients and its internal pipeline.
Verici Dx (搜索) has already applied its Olink (搜索)-certified capabilities in a collaboration with a major pharmaceutical company evaluating samples from a GLP-1 (搜索) clinical trial.
Verici Dx (搜索) plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, has achieved status as an Olink (搜索) Certified Service Provider, part of Thermo Fisher's Life Sciences Solutions. The designation, announced by the company, allows Verici Dx to provide Olink-based proteomics assay services at its CAP-certified and CLIA-accredited laboratory, supporting biomarker discovery, algorithm development, validation, application in clinical trials, and diagnostic use both internally and as a service.
Patti Connolly, Chief Operating Officer of Verici Dx (搜索), described the achievement as "an important milestone that reflects the strength of our laboratory team and our commitment to scientific excellence."
A Fully Integrated Proteomics Offering
While many Olink (搜索) service providers focus primarily on sample analysis, Verici Dx (搜索) positions itself as offering a fully integrated solution spanning three key areas. The company provides discovery-driven insights through advanced bioinformatics capabilities that enable large-scale interrogation of proteomic datasets, supporting identification of novel biomarkers and disease signatures across thousands of proteins and patient samples.
Verici Dx (搜索) also brings development-ready infrastructure, operating within a CAP/CLIA/ISO-compliant environment that provides the rigor, documentation, and quality systems required to translate discoveries into clinical-grade assays. Furthermore, the company's experience across genomics, transcriptomics, and proteomics allows for a more comprehensive understanding of disease biology and biomarker performance through its multi-omics expertise.
Rigorous Certification Standards
Olink (搜索) Certified Service Providers form a network of leading contract research organizations and service laboratories. To achieve certification, each organization must complete rigorous training, annual concordance testing, and re-certification, demonstrating its ability to deliver Olink workflows to the highest quality standards.
"What truly sets our laboratory apart is the ability to go beyond sample processing," Connolly said. "We bring together deep bioinformatics expertise and a CAP/CLIA/ISO quality system framework to support customers from biomarker discovery through product development and beyond."
Early Pharmaceutical Application in GLP-1 (搜索) Trial
Verici Dx (搜索) has already successfully applied its Olink (搜索)-certified capabilities in a recent collaboration with a major pharmaceutical company evaluating samples from a GLP-1 (搜索) clinical trial. The project leveraged a custom proteomic panel to evaluate biomarker responses in patient samples, with results contributing to ongoing scientific analyses and data submissions. This work demonstrates Verici's ability to execute complex, high-value projects with leading pharmaceutical and industry partners.
Advancing Precision Medicine in Transplantation
Connolly emphasized the broader significance of proteomics in the precision medicine landscape: "Proteomics is a critical component of precision medicine and the broader multi-omics landscape. By integrating advanced proteomics with bioinformatics expertise, Verici Dx (搜索) can help organizations generate more meaningful biological insights and translate complex data into clinically relevant applications."
Verici Dx (搜索) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. The company's lead product, Tutivia (搜索)®, is a post-kidney transplant test focused on early detection of acute rejection.
Headquartered in Cardiff, UK, and Franklin, Tennessee for the U.S., Verici Dx (搜索) operates at the intersection of laboratory and data science, developing complex models that answer clinical questions with clarity and precision. All tests are built to rigorous scientific standards and validated across inclusive, real-world patient populations to ensure clinical relevance and reliability.